Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer.
about
Analysis of estrogens and androgens in postmenopausal serum and plasma by liquid chromatography-mass spectrometry.Analysis of estrogens in serum and plasma from postmenopausal women: past present, and futureThe Role of Non-Steroidal Anti-Inflammatory Drugs in the Chemoprevention of Breast Cancer.The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.Differences in integrin expression and signaling within human breast cancer cells.Platelet-activating factor and metastasis: calcium-independent phospholipase A2β deficiency protects against breast cancer metastasis to the lung.The role of COX-2 in intestinal inflammation and colorectal cancerOsthole inhibits proliferation of human breast cancer cells by inducing cell cycle arrest and apoptosis.Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanismsSubstrate-Dependent Activity of ERK and MEK Proteins in Breast Cancer (MCF7), and Kidney Embryonic (Hek-293) Cell Lines, Cultured on Different Substrates.Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis.Different Expression of Extracellular Signal-Regulated Kinases (ERK) 1/2 and Phospho-Erk Proteins in MBA-MB-231 and MCF-7 Cells after Chemotherapy with Doxorubicin or DocetaxelA randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands.Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease preventionClinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis.Drug safety evaluation of exemestane.Concomitant resistance and early-breast cancer: should we change treatment strategies?Synergistic drug combinations from electronic health records and gene expression.Inhibition of cyclooxygenase-2-dependent survivin mediates decursin-induced apoptosis in human KBM-5 myeloid leukemia cellsCyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer.COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.Curcumol potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer.Synergistic effect between celecoxib and luteolin is dependent on estrogen receptor in human breast cancer cells.
P2860
Q30358054-96CE294C-03B7-4126-A8F2-3ABA93059450Q30432877-765DCFFE-E8EF-4470-8EB0-FFA658C8E99DQ33664316-C493D61F-FBF0-41C1-B102-4301F81B6A7CQ33737469-A1CE077C-0B7B-4276-83E4-71E9FDACD3B7Q33895607-F014E281-B433-4ACB-B88F-9598A7735E48Q33959863-CA9D9B99-EFC1-42BD-9191-6C039F09ED5BQ34782186-E69C3665-1F0C-49DB-B670-2B9FFAC395A9Q35234704-8D75BF9C-F81D-4EED-A1AE-32D5A25F7CF7Q35310290-F7A4ED96-E7AE-48F9-96EB-78A9A160C5C9Q35426181-D4777279-ECDF-427A-BB36-040E88BEE28DQ35860336-A7ECC635-C9F3-4F46-B8F6-301178E0D495Q36420170-26240258-DAA7-4E2E-86A2-08A7BACFD427Q36652542-FD12C68C-40FB-4C7C-B941-EF1493476F2BQ36903254-1AA99D11-0F72-4804-935B-7B94DC0CC0EEQ37215586-6594D6A3-C326-4553-B88D-CBA508B5CC2AQ37340750-F90E8C83-4307-4B15-8BCB-601D49CEE5D0Q37701526-8CCC9BFF-D88A-4A3F-978D-A5839C85DF3EQ37856307-5BE1D187-8EC6-403B-858B-BC4D02A166B1Q38171964-A51DF7C9-905C-4D0C-8344-BE4F69CE0DB3Q39111678-8E56C9B9-2B53-482E-ACCE-D93FE9242218Q39673400-C1468F5D-8689-4EC0-9891-5B09F01D36F5Q40814411-49EFA54D-8198-4B8E-8CF9-07C221319B4EQ43035066-24A1E7EC-13DD-4A27-BA6E-85A218DAFBA3Q43060768-3EA84BBB-85E9-4A1B-8ECD-EF9606877B4FQ49470056-099365FB-B4A9-467E-93F6-5BACDA987DE6Q53554210-9E868D78-0493-4DCA-811F-6C0398028311
P2860
Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Role of combination therapy wi ...... with metastatic breast cancer.
@en
Role of combination therapy wi ...... with metastatic breast cancer.
@nl
type
label
Role of combination therapy wi ...... with metastatic breast cancer.
@en
Role of combination therapy wi ...... with metastatic breast cancer.
@nl
prefLabel
Role of combination therapy wi ...... with metastatic breast cancer.
@en
Role of combination therapy wi ...... with metastatic breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Role of combination therapy wi ...... with metastatic breast cancer
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDN693
P577
2009-03-02T00:00:00Z